Tag: Germany
-
French PECAN reimbursement applications have started… It’s not a DiGA copy-paste
…. the fundamental differences in the French and German access paths for digital medical devices
-
March 2023 Monthly Reading List
….What we were reading in March….
-
February 2023 Monthly Reading List
Selected reads from recent press or publications in the disruptive value, commercial and reimbursement space.
-
January 2023 Market Access Reading List
Recent news and articles to think about value and evidence development. This month, the news recap comes as short reading lists.
-
December 2022 Market Access news recap
The monthy 3 minutes of selected bits of news: 62 seconds on DiPAs – digital care and nursing applications are launching in Germany Microbiome product Rebyota is now approved in the US – we are keenly watching out for access, uptake and reimbursement learnings… AIFA reimbursement committees merge Germany rare disease medicine Brineura to recevie…
-
November Market Access news recap
November market access news recap For the November recap a few news snippets from the pharma and digital health world: RWE collection in Germany, the Hemgenix gene therapy, early value assessment in England as well as the dynamic French digital health policy landscape. … as usual, three minutes of your time …
-
July 2022 Market Access news recap
Three minutes selected reimbursement and pricing news from July, including the latest updates on the reform of German AMNOG early benefit assessment & pricing process.
-
Germany: Changes to innovative drug pricing and AMNOG ahead?
The first draft of the GKV finance stabilization act (GKV FinStG) has just been presented and holds tough news for industry. An outline of the key pricing and AMNOG changes proposed: The schedule for the further consultations on the law is not yet clear. Industry has already heavily critised the draft, seeing innovation not sufficiently rewarded…